Actively Recruiting
Evaluating Acoziborole Treatment for gHAT Seropositive Individuals to Stop Disease Spread and Assess Safety
Led by Institute of Tropical Medicine, Belgium · Updated on 2026-08-27
2500
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether treating all individuals who test positive for gambiense human African trypanosomiasis gHAT serology with acoziborole can stop the spread of the disease in affected villages over three years. This study also aims to collect additional safety data for acoziborole in people who are seropositive but do not have confirmed parasitological infection. The study is coordinated by the Institute of Tropical Medicine, Belgium, with the Drugs for Neglected Diseases initiative overseeing the safety trial portion. Participants receive a single oral dose of acoziborole, with adults and adolescents aged 15 and older taking 960 mg and children aged 11 to 14 years weighing at least 30 kg taking 640 mg. Treatment is given either with or without food on the first day of the study. Follow-up visits occur at three days and three months after treatment to monitor safety and response. No placebo or active comparison treatment is used. During the study, participants are regularly assessed through home or study center visits. Researchers monitor safety, collect health information, and evaluate the interruption of disease transmission over four years. Participants must comply with follow-up schedules and agree not to join other clinical trials during the study period. The overall participation may last several years to assess both safety and impact on disease transmission.
CONDITIONS
Brief Title
Stop Transmission of Gambiense Human African Trypanosomiasis
Research Team
E
Elena Nicco
D
Digas Ngolo, MD MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here